BioSpace News Archive

Genestack Ltd. announced that its flagship multi-omics data catalog, curation and integrative search product, Omics Data Manager, has been licensed and implemented by a world-leading genomics research centre, the Wellcome Sanger Institute.

Axonics, Inc., a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021.

Evelo Biosciences, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, April 29, 2021 to report its first quarter 2021 financial results and discuss business highlights.

Owens & Minor, Inc. plans to release financial results for the first quarter of 2021 on Wednesday, May 5, 2021, before trading begins on the New York Stock Exchange.

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. – 1:00 p.m. ET on Wednesday, April 28, 2021.

In recognition of Earth Day, BD, a leading global medical technology company, reinforces its commitment to Advancing the world of health™ by affirming the first phase of its 2030+ sustainability goals – climate change targets.

“Gibson Oncology has been honored to collaborate with Dr. Danzhou Yang and her lab for the discovery and development of novel cMyc inhibitors for a major oncogene that is believed to be over-expressed in approximately 80% of all human cancers,” stated Randall B. Riggs, President & CEO of Gibson Oncology.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces that its human clinical hypertension study HYPER-H21-1 is officially underway.

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the expansion of its Phase II COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomi

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the following upcoming oral presentation at the DDW 2021 regarding AXA1665, the company’s product candidate for the reduction in risk of recurrent overt hepatic encephalopathy (OHE):